Dexlansoprazole

Product Description

Dexlansoprazole is used to treat the symptoms of gastroesophageal reflux disease (GERD; a condition in which backward flow of acid from the stomach causes heartburn and possible injury of the esophagus [tube between the throat and stomach]) in adults and children 12 years of age and older. It is also used to treat esophagitis (swelling that may damage tissues of the esophagus) in adults and children 12 years of age and older. Dexlansoprazole is used for the maintenance treatment of esophagitis and healing in adults and children 12 years of age and older. Dexlansoprazole is in a class of medications called proton pump inhibitors. It works by decreasing the amount of acid made in the stomach. (Sourced from: https://medlineplus.gov/druginfo/meds/a609017.html)

Mechanisms of Action: Proton Pump Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Bangladesh | Bosnia | Brazil | Canada | Colombia | Dominican Republic | Ecuador | Egypt | Germany | Hong Kong | India | Ireland | Israel | Italy | Jordan | Korea | Lebanon | Lithuania | Malaysia | Mexico | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United States | Uruguay | Vietnam

Approved Indications: Bile Reflux | Esophagitis | Gastroesophageal Reflux | Heartburn | Bile Reflux | Esophagitis | Gastroesophageal Reflux | Heartburn

Known Adverse Events: Abdominal Pain | Pain Unspecified | Diarrhea | Flatulence | Headache | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None